Updates are available Correction dated 2019-09-02
Click to view Correction: https://doi.org/10.1038/s41598-019-46940-z
-
Authors
Randad, Pranay R.
Dillen, Carly A.
Ortines, Roger V.
Mohr, David
Aziz, Maliha
Price, Lance B.
Kaya, Hülya
Larsen, Jesper
Carroll, Karen C.
Smith, Tara C.
Miller, Lloyd S.
Heaney, Christopher D.
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | CDC | National Institute for Occupational Safety and Health (T42OH008428, K01OH010193)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01AI101371, R01AI101371, R01AI101371)
U.S. Department of Health & Human Services | Agency for Healthcare Research and Quality (HS019966)
U.S. Department of Health & Human Services | National Institutes of Health (R01AR069502, R21AI126896)
Thrasher Research Fund (10287)
U.S. Department of Health & Human Services | NIH | National Institute of Environmental Health Sciences (R01ES026973)
National Science Foundation (1316318)
- License Information
-
More Information
Article History
Received: 9 October 2018
Accepted: 8 April 2019
First Online: 1 May 2019
Change Date: 2 September 2019
Change Type: Correction
Change Details: An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Competing Interests
: L.S.M. reports grant support from MedImmune, Regeneron Pharmaceuticals, Moderna Therapeutics, and Pfizer, which are developing therapeutics and vaccines against <i>S. aureus</i> and other pathogens.
